Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease

[1]  Mark T Mills,et al.  Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis , 2020, BMJ Open.

[2]  D. Mekahli,et al.  Activation of Calcium-Sensing Receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells , 2018, Scientific Reports.

[3]  Y. Mu,et al.  Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis , 2018, Scientific Reports.

[4]  R. Hays,et al.  Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[6]  R. Gansevoort,et al.  Tolvaptan in Later‐Stage Autosomal Dominant Polycystic Kidney Disease , 2017, The New England journal of medicine.

[7]  Y. Ubara,et al.  Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  D. Wheeler,et al.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) , 2017, Kidney international supplements.

[9]  C. Ahn,et al.  Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease , 2017, BMC Nephrology.

[10]  G. Valenti,et al.  Localization and function of the renal calcium-sensing receptor , 2016, Nature Reviews Nephrology.

[11]  F. Cosio,et al.  Volume regression of native polycystic kidneys after renal transplantation. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  Hyo Sang Kim,et al.  Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease , 2015, PloS one.

[13]  I. Narita,et al.  The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial , 2015, Clinical and Experimental Nephrology.

[14]  C. Wanner,et al.  Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease. , 2014, Kidney international.

[15]  Ajay V. Srivastava,et al.  Autosomal dominant polycystic kidney disease. , 2014, American family physician.

[16]  K. Hata,et al.  Clinical Experiences of Bixalomer Usage at Our Hospital , 2014, Therapeutic apheresis and dialysis.

[17]  H. Fujiki,et al.  Tolvaptan Delays the Onset of End-Stage Renal Disease in a Polycystic Kidney Disease Model by Suppressing Increases in Kidney Volume and Renal Injury , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[18]  R. Roepman,et al.  Polycystic liver disease: ductal plate malformation and the primary cilium. , 2014, Trends in molecular medicine.

[19]  V. Torres,et al.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. , 2014, Journal of the American Society of Nephrology : JASN.

[20]  B. Leibovich,et al.  A simple method to estimate renal volume from computed tomography. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[21]  H. Jüppner,et al.  Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH , 2013, Proceedings of the National Academy of Sciences.

[22]  Eiji Higashihara,et al.  Tolvaptan in patients with autosomal dominant polycystic kidney disease. , 2012, The New England journal of medicine.

[23]  Vladimir G. Gainullin,et al.  Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity. , 2012, The Journal of clinical investigation.

[24]  Douglas K. Atchison,et al.  Parathyroid hormone stimulates juxtaglomerular cell cAMP accumulation without stimulating renin release. , 2012, American journal of physiology. Renal physiology.

[25]  F. Rybicki,et al.  Comprehensive Comparative Study of Computed Tomography–Based Estimates of Split Renal Function for Potential Renal Donors: Modified Ellipsoid Method and Other CT-Based Methods , 2012, Journal of computer assisted tomography.

[26]  D. Cusi,et al.  Calcium-sensing receptor and calcium kidney stones , 2011, Journal of Translational Medicine.

[27]  D. Wallace,et al.  Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. , 2011, American journal of physiology. Renal physiology.

[28]  V. Gattone,et al.  Calcimimetics inhibit renal pathology in rodent nephronophthisis. , 2011, Kidney international.

[29]  A. Chapman,et al.  Imaging approaches to patients with polycystic kidney disease. , 2011, Seminars in nephrology.

[30]  M. F. Seifert,et al.  Calcimimetic inhibits late-stage cyst growth in ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.

[31]  S. Somlo,et al.  Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  CaCO,et al.  Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[33]  J. Grantham,et al.  Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.

[34]  F. Dekker,et al.  Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  A. Takakura,et al.  A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. , 2008, Kidney international.

[36]  M. Inaba,et al.  Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. , 2007, Journal of the American Society of Nephrology : JASN.

[37]  Yves Pirson,et al.  Autosomal dominant polycystic kidney disease , 1992, The Lancet.

[38]  Laurie A. Smith,et al.  Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. , 2006, Journal of the American Society of Nephrology : JASN.

[39]  T. Ikizler,et al.  Uremic malnutrition is a predictor of death independent of inflammatory status. , 2004, Kidney international.

[40]  K. Jain,et al.  Normal organ volume assessment from abdominal CT , 2004, Abdominal Imaging.

[41]  Vincent H Gattone,et al.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist , 2003, Nature Medicine.

[42]  Y. Ubara,et al.  Renal contraction therapy for enlarged polycystic kidneys by transcatheter arterial embolization in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  G. Hendy,et al.  Extracellular Calcium-sensing Receptor Is Expressed in Rat Hepatocytes , 2001, The Journal of Biological Chemistry.

[44]  E. Brown,et al.  Extracellular calcium sensing and extracellular calcium signaling. , 2001, Physiological reviews.

[45]  M F Balandrin,et al.  Calcimimetics with potent and selective activity on the parathyroid calcium receptor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  E. Brown,et al.  Localization of the extracellular Ca2+/polyvalent cation-sensing protein in rat kidney. , 1998, American journal of physiology. Renal physiology.

[47]  S. Nagao,et al.  Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  I. Ishikawa,et al.  Volume changes in autosomal dominant polycystic kidneys after the initiation of hemodialysis. , 1993, Nephron.